Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at‐risk observational study (PHAROS)

• Published in: Clinical genetics Vol. 91; no. 6; pp. 824 - 831
• Main Authors: Quaid, K.A., Eberly, S.W., Kayson‐Rubin, E., Oakes, D., Shoulson, I.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.06.2017
• Subjects: Adenine; Adult; Chorea; Cytosine; Emotional behavior; Female; Genetic Predisposition to Disease; Genetic screening; Genetic Testing; Genotype; Guanine; Humans; Huntingtin; Huntingtin Protein - genetics; Huntington disease; Huntington Disease - diagnosis; Huntington Disease - genetics; Huntington Disease - pathology; Huntington's disease; Huntingtons disease; Male; Mental depression; Middle Aged; Motor task performance; Neurodegenerative diseases; Observational studies; observational trial; Polyglutamine; Risk Factors; Social interactions; Trinucleotide repeat diseases; Trinucleotide Repeat Expansion - genetics; Trinucleotide repeats; Trinucleotide Repeats - genetics; observational trial; genetic testing; Huntington disease
• DOI: 10.1111/cge.12893
• ISSN: 0009-9163

Huntington disease (HD) is a late onset ultimately fatal neurodegenerative disorder caused by a cytosine–adenine–guanine ( CAG) triplet repeat expansion in the Huntingtin gene which was discovered in 1993. The PHAROS study is a unique observational study of 1001 individuals at risk for HD who had not been previously tested for HD and who had no plans to do so. In this cohort, 104 (10%) individuals changed their minds and chose to be tested during the course of the study but outside of the study protocol. Baseline behavioral scores, especially apathy, were more strongly associated with later genetic testing than motor and chorea scores, particularly among subjects with expanded CAG repeat length. In the CAG expanded group, those choosing to be tested were older and had more chorea and higher scores on the behavioral section of the unified Huntington's disease rating scale at baseline than those not choosing to be tested. Following genetic testing, 56% of subjects with CAG < 37 had less depression when compared to prior to testing, but depression generally stayed the same or increased for 64% of subjects in the expanded group. This finding suggests that approaches to testing must continue to be cautious, with appropriate medical, psychological and social support. Mean (SE) Beck Depression score before and after the visit at which testing was disclosed (N = 61).